Table 2:
Summary of studies examining the effect of OT agonists and antagonists on drug reward measured by either CPP or SA.
Ref | Species | Sex | Treatment | Route | Dose | Measure | Result |
---|---|---|---|---|---|---|---|
Leong et al., 2016 | Sprague Dawley rats | Female | OT | i.p. | 0.1–3 mg/kg | SA Cocaine (0.15 mg/inf) |
↓ intake |
Baracz et al., 2012 | Sprague Dawley rats | Male | OT | 1) i.p. 2) intra-NAc 3) intra-STh |
1) 0.6 mg/kg 2) 0.6 ng 3) 0.6 ng |
CPP Methamphetamine (1 mg/kg) |
1) ↓ acquisition 2) ↓ acquisition 3) ↓ acquisition |
Qi et al., 2009 | Swiss mice | Male | 1) OT alone 2) OT+ atosiban (OT antag) |
1) i.c.v. 2) i.c.v + i.c.v. |
1) 0.1–2.5 μg 2) 2.5 μg + 2 μg |
CPP Methamphetamine (2 mg/kg) |
1) ↓ acquisition ↔expression 2) ↓ OT effect on acquisition |
Cox et al., 2017 | Sprague Dawley rats | Male and female | 1) OT 2) OT 3) OT + OXA (OT antag) |
1) intra-NAc 2) i.p. 3) i.p. + intra-NAc |
1) 0.6 ug 2) 1 mg/kg 3) 1 mg/kg + 2 μg |
SA Methamphetamine (17.5 or 20 μg/inf) economic demand |
1) ↑ elasticity (α) 2) ↑ elasticity (α) 3) ↓ OT effect on elasticity |
Cox et al., 2013 | Long Evans rats | Male and female | OT | i.p. | 0.3 or 1 mg/kg | SA Methamphetamine (17.5 or 20 μg/inf) |
↓ PR breakpoint (females only) |
Carson et al., 2010 | Sprague Dawley rats | Male | OT | i.p. | 0.001–1 mg/kg | SA Methamphetamine (0.1 mg/kg/inf) |
↓intake |
Lee et al., 2019 | Sprague Dawley rat | Male | OT | i.p. | 0.1–2 mg/kg | SA Methylphenidate (0.01–0.1 mg/kg/inf) |
↓intake |
Moaddab et al., 2015 | Wistar rats | Male | 1) OT 2) OTA (OT antag) 3) OT 4) OT + OTA |
1) i.c.v. 2) i.c.v. 3) intra-NAc 3) intra-NAc |
1) 0.2 2) 0.75 μg 3) 10 ng 2) 10 + 37.5 ng |
CPP Morphine (5 mg/kg) |
1) ↔ acquisition 2) ↔ acquisition 3) ↑ expression 4) ↓ OT effect on expression |
Ibragimov et al., 1987 | Sprague Dawley rats | Male | 1) OT 2) OT + ACME-OT (OT antag) |
1) intra-NAc or intra-Hipp 2) intra-Hipp |
1) 2 ng 2) 2 + 2 ng |
SA Heroin (20 μg/inf) tolerance induced with IP injections |
1) ↓intake 2) ↑intake |
Kovács and Van Ree, 1985 | Wistar rats | Male | 1) OT 2) OT1–8 (fragment) 3) OT4–8 (fragment) 4) OT7–9 (fragment) |
s.c. | 1 μg | SA Heroin (30 μg/inf) tolerance induced with IP injections |
1) ↓ intake 2) ↓ intake 3) ↓ intake 4) ↔ intake |
Kovács et al., 1985 | CFY rats | Male | OT | s.c. | 0.05–5 Mg | SA Heroin (20 μg/inf) tolerance induced with IP injections |
↓intake |
Van Ree and de Wied, 1977 | Wistar rats | Male | 1) OT 2) tocinamide (OT frag) 3) PLG (OT frag) |
s.c. | 1) 1 μg 2) 1 μg 3) 1 μg |
SA Heroin (31 μg/inf) only 2 days acq training |
1) ↑ intake 2) ↔ intake 3) ↑ intake |
Bahi, 2015 | C56BL/6J mice | Male | carbetocin (OT analog) | ip. | 6.4 mg/kg | CPP Alcohol (2 g/kg) |
↓acquisition |
Stevenson et al., 2017 | Prairie voles | Male and female | OT | ip. | 1–10 mg/kg | SA Alcohol (15%) 2 bottle choice |
↓intake |
Tunstall et al., 2019 | Wistar rats | Male | 1) OT 2) OT 3) OT 4) PF-06655075 (OT agonist) 5) OT + L-371,257 (peripheral OT antag) |
1) ip. 2) intranasal 3) i.c.v. 4) i.c.v 5) intranasal + i.p. |
1) 0.125–1 mg/kg 2) 0.25–1 mg/kg 3) 3–30 μg 4) 30 μg 5) 1 mg/kg + 5 mg/kg |
SA Alcohol (10%) lever pressing w/vapor exposure |
1) ↓ intake 2) ↓ intake 3) ↓ intake 4) ↓ intake 5) ↔ OT effect |
King et al., 2017 | C57BL/6J mice | Male | 1) OT 2) OT + L-368,899 (OT antag) |
1) ip. 2) i.p. + i.p. |
1) 0.3–10 mg/kg 2) 1 + 10 mg/kg |
SA Alcohol (20%) drink in dark or Alcohol (12%) lever pressing |
1) ↓ intake 2) ↓ OT effect |
Peters et al., 2017 | Wistar rats | Male | OT | i.c.v. | 1 Mg | SA Alcohol (20%) 2 bottle choice |
↓intake |
MacFadyen et al., 2016 | Sprague Dawley rats | Male | OT | ip. | 0.05–0.5 mg/kg | SA Alcohol (10–15%) 3 bottle choice w/drink in dark or Alcohol (10% gel) lever pressing |
↓intake |
Abbreviations: CPP=conditioned place preference; Hipp=hippocampus; i.c.v.=intracerebroventricular; i.p.=intraperitoneal; mPFC=medial prefrontal cortex; NAc=nucleus accumbens; OT=oxytocin; SA=self-administration; s.c.=subcutaneous; STh=subthalamic nucleus.